5:49 PM
 | 
Jul 21, 2009
 |  BC Extra  |  Top Story

FoldRx reports tafamidis data

Preliminary data from a Phase II/III trial to treat familial amyloid polyneuropathy showed that tafamidis from FoldRx Pharmaceuticals Inc. (Cambridge, Mass.) missed the co-primary endpoints...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >